Virtual Presentation: SARS-CoV-2 Neutralizing Antibodies for the Treatment of COVID-19

Ajay Nirula, MD, PhD
Vice President-Immunology, Eli Lilly

Date: February 4, 2021

Time: 7:00 PM Lecture

RSVP: https://ajaynirula-ACS.eventbrite.com

Join Zoom Meeting:
https://american-chemical- society.zoom.com/j/84885079294?pwd=RXJPalFMeVNQNVlsTHFEdDdFdk0wUT09

About the Speaker
Ajay Nirula, M.D., Ph.D., is Vice President, Immunology for Lilly Research Laboratories (LRL) based at the Lilly Biotechnology Center in San Diego. Dr. Nirula joined Lilly in 2015 and is responsible for discovery research and early phase clinical development in immunology. He has most recently served as the medical leader for Lilly’s work during the COVID pandemic that lead to emergency authorization for a therapeutic neutralizing antibody. Prior to joining Lilly, Dr. Nirula held leadership positions at Amgen and Biogen Idec and was involved in several research programs and regulatory filings spanning diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, and vasculitis.

Dr. Nirula earned his undergraduate degree in molecular biology from UC Berkeley, his MD from UCLA School of Medicine, and his PhD from the University of Texas Southwestern Medical School. He subsequently joined the faculty in the Division of Rheumatology at UCSF Medical Center. He has published extensively in the scientific literature in journals such as The New England Journal of Medicine, Nature Immunology, and Journal of Experimental Medicine.

About the Presentation
Dr. Nirula will discuss the therapeutic landscape of the various neutralizing monoclonal antibodies for COVID-19.